Insmed Incorporated Board of Directors

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Ms. S. Nicole Schaeffer M.B.A.

Ms. S. Nicole Schaeffer M.B.A.

Chief People Strategy Officer

Ms. Eleanor Barisser

Ms. Eleanor Barisser

Associate Director of Investor Relations

Mr. John Drayton Wise M.B.A.

Mr. John Drayton Wise M.B.A.

Chief Commercial Officer

Mr. Michael Alexander Smith J.D.

Mr. Michael Alexander Smith J.D.

Chief Legal Officer & Corporate Secretary

Mr. Brian K. Kaspar Ph.D.

Mr. Brian K. Kaspar Ph.D.

Chief Scientific Officer

Mr. Roger Adsett M.B.A.

Mr. Roger Adsett M.B.A.

Chief Operating Officer

Mandy Fahey

Mandy Fahey

Executive Director of Corporate Communications

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.